# Sputum microbiome $\alpha$ -diversity is a key feature of the COPD frequent exacerbator phenotype

Alexa A. Pragman,<sup>1</sup> Shane W. Hodgson,<sup>2</sup> Tianhua Wu,<sup>3</sup> Allison Zank,<sup>2</sup> Cavan S. Reilly,<sup>3</sup> and Chris H. Wendt<sup>1</sup>

Affiliations: <sup>1</sup>Department of Medicine, Minneapolis VA Health Care System and Department of Medicine, University of Minnesota, Minneapolis, MN; <sup>2</sup>Research Service, Minneapolis VA Health Care System, Minneapolis, MN; <sup>3</sup>Division of Biostatistics, University of Minnesota, Minneapolis, MN.

Corresponding author: Alexa A. Pragman, Minneapolis VA Health Care System, 111F, 1 Veterans Dr., Minneapolis, MN 55417; 612-467-6671; 612-725-2273; alexa@umn.edu

Take home message: Low sputum microbiome  $\alpha$ -diversity and decreased compositional stability (increased  $\beta$ -diversity) are associated with the COPD frequent exacerbator phenotype. Low sputum microbiome  $\alpha$ -diversity is also associated with lung inflammation.

Authors' contributions: Conception and Design: A.A.P., C.S.R., and C.H.W. Data Acquisition: A.A.P., S.W.H., and A.Z. Data analysis: A.A.P., T.W., C.S.R., and C.H.W. Data interpretation: A.A.P., T.W., C.S.R., and C.H.W. Drafting the manuscript: A.A.P. Revision and final approval of the version to be published: All authors.

#### 1 ABSTRACT

2 Background: The lung microbiome is an inflammatory stimulus whose role in chronic 3 obstructive pulmonary disease (COPD) pathogenesis is incompletely understood. We 4 hypothesized that the frequent exacerbator phenotype is associated with decreased a-5 diversity and increased lung inflammation. Our objective was to assess correlations 6 between the frequent exacerbator phenotype, the microbiome, and inflammation 7 longitudinally during exacerbation-free periods. 8 Methods: We conducted a case-control longitudinal observational study of the frequent 9 exacerbator phenotype and characteristics of the airway microbiome. Eighty-one 10 subjects (41 frequent and 40 infrequent exacerbators) provided nasal, oral, and sputum

11 microbiome samples at two visits over 2-4 months. Exacerbation phenotype, relevant

12 clinical factors, and sputum cytokine values were associated with microbiome findings.

13 Results: The frequent exacerbator phenotype was associated with lower sputum 14 microbiome  $\alpha$ -diversity (p=0.0031). This decrease in  $\alpha$ -diversity among frequent 15 exacerbators was enhanced when the sputum bacterial culture was positive (p<0.001). Older age was associated with decreased sputum microbiome  $\alpha$ -diversity (p=0.0030). 16 17 Between-visit β-diversity was increased among frequent exacerbators and those who 18 experienced a COPD exacerbation between visits (p=0.025, p=0.014). Sputum cytokine 19 values did not differ based on exacerbation phenotype or other clinical characteristics. 20 IL-17A was negatively associated with α-diversity, while IL-6 and IL-8 were positively 21 associated with  $\alpha$ -diversity (p=0.012, p=0.012, p=0.0496). IL-22, IL-17A, and IL-5 levels 22 were positively associated with *Moraxella* abundance (p=0.027, p=0.0014, p=0.0020).

- 23 Conclusions: Even during exacerbation-free intervals, the COPD frequent exacerbator
- 24 phenotype is associated with decreased sputum microbiome α-diversity and increased
- 25  $\beta$ -diversity. Decreased sputum microbiome  $\alpha$ -diversity and *Moraxella* abundance are
- 26 associated with lung inflammation.

#### 27 INTRODUCTION

28

29	Chronic obstructive pulmonary disease (COPD) is a leading cause of death, however
30	the mechanisms driving its progression remain incompletely understood. One recently
31	recognized mechanism is inflammation triggered by the lung microbiome. Cycles of
32	recurrent lung infection, inflammation, and antibiotic use may disrupt the microbiome
33	with downstream consequences for lung function [1]. Even in the absence of clinical
34	infection, COPD patients with pathogenic bacteria in their airways have higher levels of
35	sputum and systemic inflammatory markers and increased pulmonary symptoms [2, 3].
36	
37	The COPD frequent exacerbator phenotype identifies a subset of patients at high risk of
38	recurrent COPD exacerbation. Frequent exacerbators (FE) suffer increased morbidity
39	and mortality compared to those who experience exacerbations less often [4–7].
40	Approximately half of COPD exacerbations are attributed to bacterial infection, and
41	pathogenic bacteria such as Haemophilus influenzae, Moraxella catarrhalis, and
42	Streptococcus pneumoniae are often identified in the lung microbiome of COPD
43	patients even during periods of stable lung disease [3].
44	
45	Inflammatory markers are increased in the sputum of FE [8–10] and COPD patients
46	colonized with potentially pathogenic bacteria [9, 11–15]. The COPD lung microbiome
47	provides an inflammatory stimulus, even in the absence of overt lung infection. In
48	particular, IL-17A, IL-8, IL-6, IL-1β, IL-22, IL-5, and leukotriene B4 (LTB4) levels in

49 sputum have been associated with various components of the COPD lung microbiome

during exacerbation-free intervals [2, 8, 11–19]. It remains unclear which particular
components of the microbiome (bacterial biomass, α-diversity, the particular taxa
present, etc.) are most closely associated with sputum inflammation or the FE
phenotype.

54

We and others have shown that the sputum microbiome of FE has lower alpha diversity compared to non-FE [18, 20–26]. Few of these studies, however, evaluate the COPD lung microbiome solely during periods of clinical stability (when findings are less influenced by exacerbation treatments), longitudinally, and including an analysis of concurrent lung inflammation. We undertook the present case-control longitudinal observational study of COPD exacerbation phenotype, the upper airway and sputum microbiome, and lung inflammation to address these gaps.

62

#### 63 **METHODS**

64 Study design and recruitment. We conducted a case-control longitudinal observational study of exacerbation phenotype and characteristics of the upper airway 65 66 and sputum microbiome. All participants were recruited from a single site and were age 67 40 or older with COPD. Frequent exacerbators (FE) had at least one severe 68 exacerbation (an exacerbation requiring hospital admission or emergency department 69 visit) in the last 12 months, in accordance with descriptions found in GOLD guidelines 70 [27]. Infrequent exacerbators (IE) must have had 0 exacerbations in the prior 24 71 months. Recruitment and all visits/samples were deferred until participants had 72 recovered for at least 1 month from the most recent exacerbation. The protocol was

73 approved by the Minneapolis VA IRB (#4541-B). Additional details on recruitment and 74 other methods can be found in the supplementary information. Samples from 22 75 participants have been previously published (PRJNA543785) [20], however all data 76 analyzed here were re-sequenced for this analysis (PRJNA944199). 77 78 Study procedures. At visit 1, participants provided their medical history, underwent 79 spirometry, completed the St. George's Respiratory Questionnaire (SGRQ), and 80 provided oral wash, nasal swab, and induced sputum samples. All participants returned 81 for a second study visit ~2 months following visit 1, where they provided information on 82 interim COPD exacerbations, repeated the SGRQ, and provided oral, nasal, and 83 sputum samples. Visit 2 was deferred (for up to 4 months following visit 1) if the 84 participant reported any COPD exacerbations or antibiotic use in the 1 month prior to 85 the visit. Exacerbation phenotype was determined at visit 1 and was not revised based 86 on exacerbations observed during the study. 87 88 Sample processing, 16S rRNA gene quantification, and MiSeg sequencing. All 89 samples and negative controls were extracted using the MO BIO PowerSoil DNA 90 Isolation Kit (QIAGEN, Germantown, MD). Extracted DNA underwent 16S rRNA gene 91 guantification using droplet digital PCR (ddPCR) and 16S rRNA gene V4 MiSeg 92 sequencing. 16S rRNA V4 sequences were processed as described in the 93 supplementary information. 94

95	Sputum culture results. The clinical microbiology laboratory performed Gram stain
96	and aerobic culture on all sputum samples. Any organism identified in culture was
97	considered a pathogen.
98	
99	Cytokine analyses. Sputum samples were submitted to the University of Minnesota
100	Cytokine Reference Laboratory for determination of LTB4, GM-CSF, IL-8, IL-6, IL-1 $\beta$ ,
101	IL-17A, IL-22, IL-5, and TNF- $\alpha$ (R&D Systems, Minneapolis, MN USA).
102	
103	Statistical analyses. Data presented is from visit 1 only (V1) or both visits (BV), as
104	described in the text. Linear regression (LR), including random effects censored
105	regression models, linear mixed models (LMM), and generalized estimating equations
106	(GEE), were used to test for associations between variables. Analyses of $\alpha$ -diversity
107	metrics were adjusted for age, forced expiratory volume in 1 second percent predicted
108	(FEV1pp), BMI, current tobacco use, and current alcohol use. $\beta$ -diversity was assessed
109	via the Bray-Curtis dissimilarity metric and illustrated via principal coordinates analysis
110	(PCoA). Univariate PERMANOVA analyses of $\beta$ -diversity were performed for each
111	anatomical site. Permutation tests were used to determine if within-subject visit 1-visit 2
112	similarity differed by permuting levels of categorical clinical factors. After eliminating
113	genera present in <10% of samples, tests of association between taxa and clinical
114	characteristics used Holm's procedure to control the family-wise error rate across all
115	taxa at 5%. GM-CSF and TNF- $\alpha$ were not analyzed and IL-22 results were
116	dichotomized (detected vs. not detected) as too few samples contained quantifiable
117	results. Random effects censored regression models were used to test for associations

between clinical or microbiome characteristics and cytokine levels (modeled as theresponse variable). All analyses were conducted in R version 3.6.0.

120

#### 121 **RESULTS**

122 **Cohort.** Eighty-one subjects consisting of 40 IE and 41 FE provided data and samples

during two visits over 2-4 months. Subjects were balanced with respect to age, gender,

124 race, ICS use, and dental care habits (Table 1). Consistent with the VA patient

125 population, most subjects were male. FE phenotype was associated with lower BMI

126 (median 27.9 vs. 30.2, p=0.022), lower FEV1pp (44.0 vs. 52.5, p<0.001), and a higher

number of COPD exacerbations in the last 12 months (median 2 vs. 0, mean 2.39 vs.

128 0). FE were less likely than IE to be current tobacco users (19.5% FE vs. 42.5% IE,

129 p=0.032). Relationships between microbiome measures at each site and clinical factors

130 (exacerbation phenotype, age, FEV1pp, ICS use, pack-years of tobacco use, current

131 tobacco use, toothbrushing frequency, SGRQ score, pathogen detection in sputum

132 samples, or experiencing a COPD exacerbation or use of an antibiotic between study

133 visits) were examined; unless mentioned, these analyses did not reveal an association.

134

Alpha Diversity. Alpha diversity was assessed using Shannon diversity, Simpson
 diversity, and Chao1 metrics. For simplicity, Simpson diversity findings are discussed in
 detail here (Figure E1), as they are largely consistent with the Shannon and Chao1
 diversity findings.

139

*Nasal samples.* No significant relationships between nasal sample Simpson diversity
and any of the evaluated clinical factors were observed.

142

143 Oral samples. In multiple models of oral wash Simpson diversity, FEV1pp (a model

144 covariate) was consistently associated with increased oral wash Simpson diversity (FE

145 phenotype V1 LR, FEV1pp coefficient estimate [CE] 0.0008, 95% confidence interval

146 [CI, 0.00002, 0.0016], p=0.027, Figure 1A; BV GEE, FEV1pp CE 0.0007, 95% CI

147 [0.0001, 0.0013], p=0.023). In light of this association, we further evaluated potential

relationships between FE phenotype, FEV1pp and Simpson diversity. In a model of FE

149 phenotype, FEV1pp, and their interaction, FE phenotype and the interaction of FE

150 phenotype and FEV1pp were associated with oral wash Simpson diversity (interaction

151 BV GEE CE 0.0010, 95% CI [0.00002, 0.0020], p=0.048). Higher SGRQ scores

152 (indicating worse quality of life) were associated with lower oral wash Simpson diversity

153 (V1 LR, CE -0.0007, 95% CI [-0.0013, -0.00011], p=0.018, Figure 1B; and BV GEE, CE

154 -0.0005, 95% CI [-0.0009, -0.0001], p=0.020).

155

*Sputum samples.* The FE phenotype was associated with lower Simpson diversity in
sputum at V1 and BV (V1 LR, CE -0.077, 95% CI [-0.15, -0.0048], p=0.041, Figure E2;
BV GEE, CE -0.075, 95%CI [-0.12, -0.025], p=0.0031). Older age (another model
covariate) was also associated with lower sputum Simpson diversity in a model of
exacerbation phenotype (V1 LR, age CE -0.0090, 95% CI [-0.015, -0.0025], p=0.0080,
Figures 2a and E3; BV GEE, age CE -0.0074, 95% CI [-0.012, -0.0025], p=0.0030).

When exacerbation phenotype, age, and their interaction were included in a model of
sputum α-diversity, their interaction was significantly associated with lower Simpson
diversity (V1 LR, interaction CE -0.013, 95% CI [-0.024, -0.0024], p=0.020, Figure 2A;
BV GEE, interaction CE -0.0099, 95% CI [-0.018, -0.0017], p=0.017). This shows that
the association between exacerbation phenotype and sputum Simpson diversity differs
based on age.

169

170 Sputum samples from 6 subjects (3 FE and 3 IE) were positive for clinically relevant

171 respiratory pathogens (Moraxella catarrhalis, Haemophilus influenziae, methicillin-

172 resistant Staphylococcus aureus, and Klebsiella pneumoniae) at visit 1. Presence of a

173 pathogen was associated with lower sputum Simpson diversity at V1 and BV (V1 LR,

174 CE -0.19, 95% CI [-0.31, -0.074], p=0.0028; BV LMM, CE -0.20, 95% CI [-0.26, -0.14],

p<0.001). When FE phenotype, pathogen, and their interaction were included in the

model, only their interaction was significant at V1 and BV (V1 LR, CE -0.46, 95% CI [-

177 0.63, -0.30], p<0.001, Figure 2B; BV LMM, CE -0.27, 95% CI [-0.38, -0.15], p<0.001).

178 This shows that the association between sputum culture positivity during clinically stable

179 periods and Simpson diversity differs based on exacerbation phenotype.

180

In summary, sputum  $\alpha$ -diversity is associated with FE phenotype, age, and pathogen detection in sputum culture during clinically stable periods. The association between FE phenotype and decreased sputum  $\alpha$ -diversity is also modified by older age or the identification of a pathogen from sputum culture.

185

Alpha diversity over time. Visit 1 values were significantly associated with visit 2 values 186 187 at all sites (data not shown). Self-reported COPD exacerbation or self-reported use of 188 an antibiotic for any indication in between study visits was not associated with  $\alpha$ -189 diversity at visit 2 (when baseline values were included in the models). Exacerbation 190 phenotype, age, FEV1pp, current tobacco use, pack-years of tobacco use, and SGRQ 191 score were not associated with a change in α-diversity between study visits. 192 193 Beta diversity. Environmental, equipment, and regent control samples were distinct 194 from subject samples (Figure E4). After subsampling to include only subject samples 195 from visit 1, PCoA revealed significant clustering by anatomic site (PERMANOVA, 196 p=0.001 for all pair-wise testing; Figure 3). 197 198 PERMANOVA analyses. Clustering on PCoA based on exacerbation phenotype and 199 other clinical factors was investigated using PERMANOVA analyses. The analyses 200 were conducted at each anatomic site separately and using visit 1 data, unless noted below. At visit 1, nasal samples clustered based on FEV1pp (PERMANOVA, R<sup>2</sup>=0.029, 201 202 p=0.033). Several other PERMANOVA results with p<0.10 are provided in Table E1. 203 When visit 2 data were analyzed, sputum samples from participants who reported 204 between-visit antibiotic use for any indication clustered separately from participants who did not report between-visit antibiotic use (PERMANOVA,  $R^2$ =0.029, p=0.049). 205 206 207 Beta-diversity over time. Visit 1 samples were compared to corresponding visit 2

samples for all subjects and sites to assess the stability of microbiome composition over

time. Among nasal samples, the FE phenotype and antibiotic use between study visits
was associated with decreased similarity between paired samples (permutation testing
[P], p=0.044 and p=0.032, respectively). There were no associations with oral wash
similarity between visits. Among sputum samples, the FE phenotype and experiencing a
COPD exacerbation between visits were associated with lower similarity between paired
samples (P, p=0.025 and p=0.014, respectively; Figure 4).

215

216 Bacterial taxa. We investigated the bacterial taxa present in each sample to determine 217 potential associations with relevant clinical factors (97 tests). Many taxa were 218 associated with clinical site, in accordance with clinical findings and the human 219 microbiome literature. Nasal samples were enriched with Corynebacterium, 220 Staphylococcus, Cutibacterium, and Moraxella (among others) compared with oral and 221 sputum samples (LR, all p<0.05 following Holm correction; Table E2). Oral and sputum 222 samples were enriched with Veillonella, Rothia, Prevotella, Streptococcus, and 223 Haemophilus (among others) when compared with nasal samples (LR, all p<0.05 224 following Holm correction; Table E3). Across all anatomic sites, Mannheimia abundance 225 was positively associated with age (LR, p=0.0014); Mogibacterium abundance was 226 lower among FE compared to IE (p=0.029); Leuconostoc abundance was negatively 227 associated with FEV1pp (p=0.020); Bulleidia abundance was higher among current 228 tobacco users (p=0.013); and *Pseudomonas* abundance was positively associated with 229 pack-years of tobacco use (p<0.0001).

230

231 Sputum cytokine analyses. Sputum sample cytokine levels were tested for an 232 association with clinical factors and sputum microbiome characteristics. Cytokines were 233 chosen for analysis based on prior reported associations with culture or microbiome 234 results, and analyses of the 7 evaluable cytokines are provided here. Samples from all 235 available visits were analyzed using GEE or random effects censored regression 236 models, as appropriate, accounting for visit. 237 238 Cytokines associated with clinical characteristics. None of the clinical factors 239 (exacerbation phenotype, age, FEV1pp, pack-years of tobacco exposure, current 240 tobacco use, or SGRQ score) were associated with cytokine levels in a random effects 241 censored regression model. 242 243 Cytokines associated with Alpha diversity (Simpson). Three sputum cytokines were

244 associated with sputum sample  $\alpha$ -diversity on univariate analysis. IL-17A levels were 245 negatively associated with Simpson diversity, while IL-6 and IL-8 were positively 246 associated with Simpson diversity (random effects censored regression model, IL-17A 247 CE -1.3, 95% CI [-2.2, -0.50], p=0.012; IL-6 CE 6.0, 95% CI [2.2, 9.8], p=0.012; and IL-8 248 CE 4.2, 95% CI [1.0, 7.4], p=0.0496; respectively; Figure 5). IL-22, IL-5, IL-1 $\beta$ , and 249 LTB4 were not associated with Simpson diversity.

250

251 Cytokines associated with positive bacterial sputum culture. Presence of typical COPD

252 pathogens in sputum samples, such as Streptococcus, Moraxella, or Haemophilus,

have been associated with exacerbation phenotype, increased inflammation, and

decreased α-diversity. We found that IL-22, IL-17A, and IL-5 levels were positively
associated with *Moraxella* abundance (GEE with Holm correction, IL-22 CE 10.26, 95%
CI [3.96, 16.55], p=0.027; random effects censored regression model with Holm
correction, IL-17A CE 2.01, 95% CI [1.02, 2.99], p=0.0014; and IL-5 CE 1.87, 95% CI [0.
93, 2.81], p=0.002, respectively; Figure 6). There were no significant associations with
other cytokines or the genera *Streptococcus* or *Haemophilus*.

260

#### 261 **DISCUSSION**

262 Our case-control longitudinal observational study of the upper airway and sputum 263 microbiome during periods of clinical stability identified low sputum microbiome  $\alpha$ -264 diversity as a key feature of the COPD frequent exacerbator phenotype. In turn, low 265 sputum microbiome  $\alpha$ -diversity was associated with airway bacterial colonization and 266 lung inflammation, two other characteristics consistent with the increased morbidity and 267 mortality associated with the frequent exacerbator phenotype. Additionally, the frequent 268 exacerbator phenotype was associated with decreased microbiome compositional 269 stability (increased  $\beta$ -diversity) on longitudinal sputum sampling. These findings suggest 270 that low  $\alpha$ -diversity and an unstable sputum microbiome are key features of the frequent 271 exacerbator phenotype.

272

In addition to our findings on the frequent exacerbator phenotype, we also detected
associations between the sputum, oral, or nasal microbiome and age and COPD-related
symptom severity. Also, among the small number of subjects who experienced an
exacerbation between study visits, we observed compositional changes (increased β-

277 diversity) in the microbiome following the occurrence of a COPD exacerbation. Our 278 study determined that the frequent exacerbator phenotype is associated with low 279 sputum microbiome  $\alpha$ -diversity. Low  $\alpha$ -diversity among FE has been found by many— 280 but not all-investigators, possibly related to differences in how exacerbation frequency 281 was analyzed [20, 22–26, 28, 29]. In the case of the sputum microbiome, this 282 homogeneity was enhanced among older participants and among participants with 283 airway bacterial colonization. This phenotype also correlated with increased 284 Mogibacterium, an oral taxon associated with oral inflammation and stable COPD [30, 285 31]. 286 287 In this study and others, older age was associated with decreased a-diversity among 288 sputum samples [23, 28]. Here, we also determined that older age is associated with a 289 further decrease in  $\alpha$ -diversity among FE. Although aging is associated with an 290 increased likelihood of COPD diagnosis—as well as increased susceptibility to lung 291 infections and declines in lung function—the associations between aging and the 292 microbiome are relatively understudied. The aging COPD lung microbiome and the gut-293 lung axis may exist at a juncture between declining lung function, immunosenescence, 294 nutritional changes, and increased antibiotic use [32]. Our work suggests that age itself 295 may influence the COPD lung microbiome, possibly via mechanisms independent of 296 typical factors (such as COPD exacerbations) that are known to influence the lung 297 microbiome.

298

299 Our analysis of associations between the microbiome and tobacco use encompassed both pack-years of tobacco use as well as current (vs. former) tobacco use status. 300 301 Consistent with many of the previous studies [33-35], which identified more tobacco-302 associated microbiome changes of the upper vs. lower airway, we identified that greater 303 pack-years of tobacco exposure were associated with increased Pseudomonas 304 abundance, while current (vs. former) tobacco use was associated with increased 305 Bulleidia abundance, primarily in the oropharynx. Bulleidia has previously been 306 associated with tobacco use and lung cancer [36, 37]. 307 308 The present study also evaluated the longitudinal stability of the upper and lower airway 309 microbiome. Although microbiome findings were generally similar on repeated sampling 310 (low  $\beta$ -diversity), we identified several scenarios in which  $\beta$ -diversity was increased. The 311 sputum microbiome of FE exhibited decreased similarity (increased  $\beta$ -diversity) 312 compared with IE. Subjects who experienced a COPD exacerbation between study 313 visits also exhibited decreased compositional similarity vs. those who did not report 314 interim exacerbations. 315

We also found significant differences in sputum cytokine levels which associated with
sputum microbiome α-diversity, but not related to exacerbation phenotype, COPD
severity, age, tobacco use, or COPD-related quality of life. Low sputum α-diversity was
associated with increased concentrations of sputum IL-17A and decreased
concentrations of IL-6 and IL-8. *Moraxella* abundance in the sputum microbiome was
also associated with increased concentrations of IL-22, IL-17A, and IL-5. IL-17A, IL-22,

322 and IL-6 are key mediators of a Th17 response, often at mucosal sites [38]. IL-8 is a 323 neutrophil chemoattractant. IL-5 is involved in Th2 responses and eosinophil 324 recruitment. In prior COPD studies, elevated sputum IL-6 and IL-8 levels have been 325 associated with tobacco use, lower FEV1pp, frequent exacerbations, and acute 326 exacerbation (vs. clinical stability) [8, 39–42]. Our finding of a positive association 327 between IL-6 and IL-8 levels and  $\alpha$ -diversity is somewhat unexpected, but it is possible 328 that the acute rise in IL-6 and IL-8 observed during exacerbations is not reflected in our 329 samples, which were collected during exacerbation-free intervals. Furthermore, few 330 investigators have assessed the sputum microbiome—specifically low  $\alpha$ -diversity—in 331 relationship to inflammatory cytokines. 332 333 Our manuscript has several strengths. We used well-defined FE and IE phenotypes 334 consistent with GOLD guidelines [27], allowing us address associations between the 335 microbiome and exacerbation phenotype. We deferred all study visits for 1 month 336 following a COPD exacerbation or antibiotic use for any reason, in order to focus on the 337 microbiome during periods of clinical stability. This approach minimizes, to the extent 338 possible in an observational study of COPD, the influence of recent antibiotic or 339 systemic steroid use on our microbiome findings. Lastly, our longitudinal approach 340 allowed us to assess the stability of microbiome composition in relationship to 341 exacerbation phenotype and recent COPD exacerbations. Our use of sputum 342 inflammatory cytokines, in the context of the microbiome findings, identified clinical 343 correlates of our microbiome findings.

344

345 Despite these strengths, our study had several relative weaknesses. We are unable to 346 assess the influence of sex on the microbiome, as our single-center study was 347 conducted at a Veterans Affairs hospital with a limited female population. Sputum 348 samples may be contaminated by saliva during expectoration and therefore may not 349 reflect only the lower airway microbiome. Despite this potential limitation, we note that 350 most of our key microbiome findings were identified only in the sputum microbiome and 351 not identified in the oral microbiome. This suggests that sputum analysis can identify 352 microbiome associations unique to the lower airways, despite potential upper airway 353 contamination. 354 355 In conclusion, we found that FEs exhibit lower sputum microbiome  $\alpha$ -diversity, which is 356 enhanced by older age or bacterial colonization of the airways. Sputum microbiome α-357 diversity is a significant correlate of lung inflammation. The sputum microbiome

358 composition of FEs changes more over time when compared to the compositional

359 stability of IEs.

#### 360 ACKNOWLEDGEMENTS

361

362	The authors wish to thank Ms. Susan Johnson, LPN, for assistance with study
363	recruitment. This material is based upon work supported by the Department of Veterans
364	Affairs, Veterans Health Administration, Office of Research and Development (Clinical
365	Sciences Research and Development). The views expressed in this article are those of
366	the authors and do not necessarily reflect the position or policy of the Department of
367	Veterans Affairs or the United States government. This publication was supported by
368	Grant Number 1UL1RR033183 from the National Center for Research Resources
369	(NCRR) and by Grant Number 8 UL1 TR000114-02 from the National Center for
370	Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) to
371	the University of Minnesota Clinical and Translational Science Institute (CTSI). Its
372	contents are solely the responsibility of the authors and do not necessarily represent the
373	official views of the CTSI or the NIH. The University of Minnesota CTSI is part of a
374	national Clinical and Translational Science Award (CTSA) consortium created to
375	accelerate laboratory discoveries into treatments for patients.
376	
377	Conflict of interest: None of the authors declare any potential conflict of interest.
378	

Financial Support: U.S. Department of Veterans Affairs Office of Research and
Development 1 IK2 CX001095, 1 I01 CX002130, and NIH/University of Minnesota
Clinical and Translational Science Institute 1UL1RR033183, 8 UL1 TR000114-02.

#### 382 **Tables:**

383

#### **Table 1. Subject Baseline Characteristics**

	Infrequent	Frequent	Overall p
	Exacerbator	Exacerbator	value *
	(N=40)	(N=41)	(N=81)
Gender, Male (%)	40 (100)	40 (97.6)	80 (98.8) 1.00
Age, median (IQR)	69 (5)	69 (8)	69 (7) 0.632
Race, Caucasian white (%)	37 (92.5)	40 (97.6)	77 (95.1) 0.359
BMI, median (IQR)	30.2 (7.79)	27.93 (9.26)	29.57 0.022 (8.46)
COPD Severity (%)			(0110)
Moderate	24 (60)	14 (34.1)	38 (46.9)
Severe	14 (35)	18 (43.9)	32 (39.5)
Very Severe	2 (5)	9 (22)	11 (13.6)
FEV <sub>1</sub> % predicted, median (IQR)	52.5 (19)	44 (17)	48 (19) <
			0.001
COPD exacerbations in the last 12	0 (0)	2 (1)	1 (2) <
months, median (IQR)			0.001
COPD hospitalizations in the last 12	0 (0)	0 (1)	0 (0) <
months, median (IQR)			0.001
Inhaled corticosteroids, Yes (%)	11 (27.5)	14 (34.1)	25 (30.9) 0.632
Pack-years of smoking, median (IQR)	41 (23.12)	50 (23)	50 (24.5) 0.059
Current tobacco use, Yes (%)	17 (42.5)	8 (19.5)	25 (30.9) 0.032
Current alcohol use, Yes (%)	24 (60)	32 (78)	56 (69.1) 0.096
Brush teeth $\geq$ once daily (%) <sup><i>a</i></sup>	30 (75) <sup>a</sup>	30 (75) <sup>a</sup>	60 (75) <sup>a</sup> 1.00
SGRQ Score, median (IQR)	43.62 (10.49)	52.4 (20.6)	47.29 0.074
			(17.84)

385 Frequencies and percentages are presented unless specified otherwise. BMI, body

386 mass index; COPD, chronic obstructive pulmonary disease; FEV1% predicted, forced

387 expiratory volume in 1 s, percent of predicted value; IQR, interquartile range; SGRQ, St.

388 George's Respiratory Questionnaire

<sup>389</sup> \*A Two-Sample t test was conducted for all continous variables and a Fisher exact test

390 for all categorical variables

<sup>a</sup>One subject did not provide frequency of brushing teeth

#### 393 **REFERENCES**

394

- 395 1. Sethi S, Maloney J, Grove L *et al.* Airway inflammation and bronchial bacterial
- 396 colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med
- 397 2006; 173: 991-998.
- 398 2. Desai H, Eschberger K, Wrona C et al. Bacterial Colonization Increases Daily
- 399 Symptoms in Patients with Chronic Obstructive Pulmonary Disease. Ann Am
  400 Thorac Soc 2014; 11: 303-309.
- 401 3. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in

402 2000: a state-of-the-art review. Clinical Microbiology Reviews 2001; 14: 336-363.

403 4. Carolan BJ, Sutherland ER. Clinical phenotypes of chronic obstructive pulmonary

disease and asthma: recent advances. J Allergy Clin Immunol 2013; 131: 627-34;

405 quiz 635.

406 5. Hurst JR, Vestbo J, Anzueto A *et al.* Susceptibility to exacerbation in chronic

407 obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138.

408 6. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P et al. Severe acute

409 exacerbations and mortality in patients with chronic obstructive pulmonary disease.

410 Thorax 2005; 60: 925-931.

411 7. Spencer S, Jones PW. Time course of recovery of health status following an

- 412 infective exacerbation of chronic bronchitis. Thorax 2003; 58: 589-593.
- 413 8. Bhowmik A, Seemungal TA, Sapsford RJ *et al.* Relation of sputum inflammatory

414 markers to symptoms and lung function changes in COPD exacerbations. Thorax

415 2000; 55: 114-120.

416	9.	Garcha DS, Thurston SJ, Patel AR et al. Changes in prevalence and load of airway
417		bacteria using quantitative PCR in stable and exacerbated COPD. Thorax 2012;
418		67: 1075-1080.
419	10.	Thomsen M, Ingebrigtsen TS, Marott JL et al. Inflammatory biomarkers and
420		exacerbations in chronic obstructive pulmonary disease. JAMA 2013; 309: 2353-
421		2361.
422	11.	Barker BL, Haldar K, Patel H et al. Association between pathogens detected using
423		quantitative polymerase chain reaction with airway inflammation in COPD at stable
424		state and exacerbations. Chest 2014; 147: 46-55.
425	12.	Hill AT, Campbell EJ, Hill SL et al. Association between airway bacterial load and
426		markers of airway inflammation in patients with stable chronic bronchitis. Am J
427		Med 2000; 109: 288-295.
428	13.	Marin A, Garcia-Aymerich J, Sauleda J et al. Effect of Bronchial Colonisation on
429		Airway and Systemic Inflammation in Stable COPD. COPD 2012; 9: 121-130.
430	14.	Patel IS, Seemungal TA, Wilks M et al. Relationship between bacterial colonisation
431		and the frequency, character, and severity of COPD exacerbations. Thorax 2002;
432		57: 759-764.
433	15.	Stockley RA, Hill AT, Hill SL et al. Bronchial inflammation: its relationship to
434		colonizing microbial load and alpha(1)-antitrypsin deficiency. Chest 2000; 117:
435		291S-3S.
436	16.	Singh R, Mackay AJ, Patel AR et al. Inflammatory thresholds and the species-
437		specific effects of colonising bacteria in stable chronic obstructive pulmonary

438 disease. Respir Res 2014; 15: 114.

43	9 17.	Ramsheh MY, Haldar K, Esteve-Codina A et al. Lung microbiome composition and
44	0	bronchial epithelial gene expression in patients with COPD versus healthy
44	1	individuals: a bacterial 16S rRNA gene sequencing and host transcriptomic
44	2	analysis. Lancet Microbe 2021; 2: e300-e310.
44	3 18	Wang Z, Locantore N, Haldar K et al. Inflammatory Endotype-associated Airway
44	4	Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and
44	5	Exacerbations: A Multicohort Longitudinal Analysis. Am J Respir Crit Care Med
44	6	2021; 203: 1488-1502.
44	7 19	Tufvesson E, Bjermer L, Ekberg M. Patients with chronic obstructive pulmonary
44	8	disease and chronically colonized with Haemophilus influenzae during stable
44	9	disease phase have increased airway inflammation. Int J Chron Obstruct Pulmon
45	0	Dis 2015; 10: 881-889.

451 20. Pragman AA, Knutson KA, Gould TJ *et al.* Chronic obstructive pulmonary disease

452 upper airway microbiota alpha diversity is associated with exacerbation phenotype:

453 a case-control observational study. Respir Res 2019; 20: 114.

454 21. Wang Z, Singh R, Miller BE *et al.* Sputum microbiome temporal variability and

455 dysbiosis in chronic obstructive pulmonary disease exacerbations: an analysis of

456 the COPDMAP study. Thorax 2017; 73: 331-338.

457 22. Mayhew D, Devos N, Lambert C et al. Longitudinal profiling of the lung microbiome

458 in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD

459 exacerbations. Thorax 2018; 73: 422-430.

460	23.	Li W, Wang B, Tan M et al. Analysis of sputum microbial metagenome in COPD
461		based on exacerbation frequency and lung function: a case control study. Respir
462		Res 2022; 23: 321.
463	24.	Dicker AJ, Huang JTJ, Lonergan M et al. The sputum microbiome, airway
464		inflammation, and mortality in chronic obstructive pulmonary disease. J Allergy Clin
465		Immunol 2021; 147: 158-167.
466	25.	Yang CY, Li SW, Chin CY et al. Association of exacerbation phenotype with the
467		sputum microbiome in chronic obstructive pulmonary disease patients during the
468		clinically stable state. J Transl Med 2021; 19: 121.
469	26.	Su L, Qiao Y, Luo J et al. Exome and Sputum Microbiota as Predictive Markers of
470		Frequent Exacerbations in Chronic Obstructive Pulmonary Disease. Biomolecules
471		2022; 12
472	27.	Agustí A, Celli BR, Criner GJ et al. Global Initiative for Chronic Obstructive Lung
473		Disease 2023 Report: GOLD Executive Summary. Eur Respir J 2023: 61

474 28. Millares L, Pascual S, Montón C *et al.* Relationship between the respiratory

475 microbiome and the severity of airflow limitation, history of exacerbations and

476 circulating eosinophils in COPD patients. BMC Pulm Med 2019; 19: 112.

477 29. Wang Z, Maschera B, Lea S *et al.* Airway host-microbiome interactions in chronic
478 obstructive pulmonary disease. Respir Res 2019; 20: 113.

479 30. Li Q, Pu Y, Lu H et al. Porphyromonas, Treponema, and Mogibacterium promote

- 480 IL8/IFNγ/TNFα-based pro-inflammation in patients with medication-related
- 481 osteonecrosis of the jaw. J Oral Microbiol 2020; 13: 1851112.

482	31.	Huang YJ, Sethi S, Murphy T et al. Airway microbiome dynamics in exacerbations
483		of chronic obstructive pulmonary disease. J Clin Microbiol 2014; 52: 2813-2823.
484	32.	Saint-Criq V, Lugo-Villarino G, Thomas M. Dysbiosis, malnutrition and enhanced
485		gut-lung axis contribute to age-related respiratory diseases. Ageing Res Rev 2020;
486		66: 101235.
487	33.	Morris A, Beck JM, Schloss PD et al. Comparison of the respiratory microbiome in
488		healthy nonsmokers and smokers. Am J Respir Crit Care Med 2013; 187: 1067-
489		1075.
490	34.	Pfeiffer S, Herzmann C, Gaede KI et al. Different responses of the oral, nasal and
491		lung microbiomes to cigarette smoke. Thorax 2022; 77: 191-195.
492	35.	Ying KL, Brasky TM, Freudenheim JL et al. Saliva and Lung Microbiome
493		Associations with Electronic Cigarette Use and Smoking. Cancer Prev Res (Phila)
494		2022; 15: 435-446.
495	36.	Camelo-Castillo AJ, Mira A, Pico A et al. Subgingival microbiota in health
496		compared to periodontitis and the influence of smoking. Front Microbiol 2015; 6:
497		119.
498	37.	Tsay J-CJ, Wu BG, Badri MH et al. Airway Microbiota Is Associated with
499		Upregulation of the PI3K Pathway in Lung Cancer. American Journal of
500		Respiratory and Critical Care Medicine 2018; 198: 1188-1198.
501	38.	Schnell A, Littman DR, Kuchroo VK. $T_H 17$ cell heterogeneity and its role in tissue
502		inflammation. Nat Immunol 2023; 24: 19-29.

503	39.	Hacievliyagil SS, Gunen H, Mutlu LC et al. Association between cytokines in
504		induced sputum and severity of chronic obstructive pulmonary disease. Respir
505		Med 2006; 100: 846-854.
506	40.	Wedzicha JA, Seemungal TA, MacCallum PK et al. Acute exacerbations of chronic
507		obstructive pulmonary disease are accompanied by elevations of plasma
508		fibrinogen and serum IL-6 levels. Thromb Haemost 2000; 84: 210-215.
509	41.	Wilkinson TM, Hurst JR, Perera WR et al. Effect of interactions between lower
510		airway bacterial and rhinoviral infection in exacerbations of COPD. Chest 2006;
511		129: 317-324.
512	42.	Aaron SD, Angel JB, Lunau M et al. Granulocyte inflammatory markers and airway
513		infection during acute exacerbation of chronic obstructive pulmonary disease. Am J
514		Respir Crit Care Med 2001; 163: 349-355.
515		

#### 517 **FIGURE LEGENDS.**

#### 518 Figure 1. Oral Wash α-diversity is associated with FEV1pp and COPD-related

- 519 **quality of life.** A. Oral wash Simpson diversity at visit 1 is associated with FEV1pp (a
- 520 model covariate) in a model of FE phenotype (FE phenotype V1 LR, FEV1pp CE
- 521 0.0008, 95% CI [0.00002, 0.0016], p=0.027. FEV1pp is associated with low Simpson
- 522 diversity in the adjusted model. B. Oral wash Simpson diversity at visit 1 is associated
- 523 with SGRQ score at Visit 1 (LR, CE -0.0007, 95% CI [-0.0013, -0.00011], p=0.018).
- 524 Higher SGRQ scores indicate worse COPD-related quality of life.
- 525

#### 526 Figure 2. Sputum α-diversity is associated with exacerbation phenotype, age, and

527 **culture results.** A. Both the FE phenotype and older age were significantly associated

- 528 with lower Simpson diversity at Visit 1 (LR, CE -0.077, 95% CI [-0.15, -0.0048], p=0.041
- and CE -0.0090, 95% CI [-0.015, -0.0025], p=0.0080, respectively). When the
- 530 interaction of exacerbation phenotype and age was added to the model, only the
- 531 interaction of age and exacerbation phenotype was significant (LR, CE -0.013, 95% CI
- 532 [-0.024, -0.0024], p=0.020). The regression lines represent the association between
- 533 phenotype, age, and Simpson diversity. The significant interaction between age and
- 534 phenotype indicates that older FE have lower sputum  $\alpha$ -diversity than younger FE or
- 535 older IE. B. Presence of a pathogen in sputum culture was associated with lower
- 536 sputum Simpson diversity at V1 (LR, CE -0.19, 95% CI [-0.31, -0.074], p=0.0028). When
- 537 FE phenotype, pathogen, and their interaction were included in the model, only their
- 538 interaction was significant (V1 LR, CE -0.46, 95% CI [-0.63, -0.30], p<0.001). The

- association between sputum culture positivity during clinically stable periods and
- 540 Simpson diversity differs based on exacerbation phenotype.
- 541
- 542 Figure 3. Beta-diversity reveals clustering by anatomic site. Principal coordinate
- 543 analysis using Bray-Curtis dissimilarity on visit 1 samples demonstrating significant
- 544 clustering by anatomic site (PERMANOVA, p=0.001 for all pair-wise testing). Centroids
- 545 are illustrated by black dots, with lines connecting each sample to its corresponding
- 546 centroid.
- 547

548 **Figure 4. Within-subject microbiome composition stability.** Self-report of a COPD

549 exacerbation between study visits corresponded with an increase in microbiome

550 compositional changes (increased β-diversity, or a decrease in sample similarity)

551 compared with subjects who did not experience a COPD exacerbation between study

- 552 visits.
- 553

554 **Figure 5. Multiple sputum cytokines are associated with α-diversity.** Increased

sputum concentrations of IL-17A were associated with decreased Simpson diversity in

556 the sputum, while increased sputum concentrations of IL-6 and IL-8 were associated

557 with increased Simpson diversity (random effects censored regression model, IL-17A

558 CE -1.3, 95% CI [-2.2, -0.50], p=0.012; IL-6 CE 6.0, 95% CI [2.2, 9.8], p=0.012; and IL-8

559 CE 4.2, 95% CI [1.0, 7.4], p=0.0496; respectively).

560

#### 561 Figure 6. Sputum cytokines are associated with *Moraxella* abundance. Increased

- 562 sputum concentrations of IL-22, IL-17A, and IL-5 were correlated with increased
- abundance of *Moraxella* in sputum samples (GEE with Holm correction, IL-22 CE 10.26,
- 564 95% CI [3.96, 16.55], p=0.027; random effects censored regression model with Holm
- 565 correction, IL-17A CE 2.01, 95% CI [1.02, 2.99], p=0.0014; and IL-5 CE 1.87, 95% CI
- 566 [0.93, 2.81], p=0.002, respectively).

567

#### 568 **FIGURES.**













Phenotype Frequent Exacerbator Infrequent Exacerbator



# Phenotype Frequent Exacerbator Infrequent Exacerbator











## Sample

- Nasal
- Oral Wash
- Sputum



### Group

- Negative Control
- Nasal
- Oral Wash
- Sputum